Get the Stockscreener App
8.85
5.48%
0.46
Pre-market:
8.89
0.04
+0.45%
Biohaven Ltd stock is traded at $8.85, with a volume of 2.90M.
It is up +5.48% in the last 24 hours and down -18.21% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$8.39
Open:
$8.38
24h Volume:
2.90M
Relative Volume:
1.38
Market Cap:
$1.33B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.2715
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
-1.99%
1M Performance:
-18.21%
6M Performance:
-8.10%
1Y Performance:
-45.54%
1-Day Range:
$8.38
$9.27
1-Week Range:
$8.22
$9.305
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
8.85 | 1.28B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure - Stock Titan
BHVN Stock Price Prediction 2025-2026 | Biohaven Pharmaceutical Holding Co Ltd Forecast - 24/7 Wall St.
Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving? - simplywall.st
Biohaven Ltd. (BHVN) Receives a Hold from Bernstein - The Globe and Mail
BHVN Technical Analysis | Trend, Signals & Chart Patterns | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Morgan Stanley Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating - Moomoo
TradingKey - TradingKey
BHVN Stock Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside - TradingView
Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Biohaven stock rating ahead of trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Biohaven stock rating ahead of trial - Investing.com
Biohaven: Hold Rating Reiterated as Clinical and Competitive Uncertainties Persist; Price Target Maintained at $10 - TipRanks
H.C. Wainwright Maintains Biohaven(BHVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
How Biohaven Ltd. (BHVN) Affects Rotational Strategy Timing - Stock Traders Daily
MSN Money - MSN
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf RegistrationWhat's Changed - Yahoo Finance
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures - TipRanks
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo! Finance Canada
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
A Quick Look at Today's Ratings for Biohaven(BHVN.US), With a Forecast Between $12 to $30 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding Plans - Yahoo Finance
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
MSN - MSN
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Ltd files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) files shelf to register shares, debt and warrants - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83 - Moomoo
Two late-stage readouts due in 2026 as Biohaven cash reaches $351.8M - Stock Titan
Biohaven : Reports Recent Business Developments and First Quarter 2026 Financial Results - marketscreener.com
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biohaven (NYSE: BHVN) cuts Q1 2026 loss while funding late-stage drug pipeline - Stock Titan
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - ChartMill
Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan - Stock Titan
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio - simplywall.st
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):